Industry leader in patch technology
ProSolus®, Inc., Mission’s wholly-owned subsidiary, offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal and trans-mucosal drug delivery products to treat a variety of health conditions.
Acquired by Mission in May 2015, ProSolus, Inc., headquartered in Miami, Florida, closely follows Mission’s mantra to improve patient access to products that enhance quality and enjoyment of life. ProSolus has significantly improved the wearability of transdermal patches, offering more desirable, compact sizes that stay in place while working effectively. Few therapies on the market today are as effective or easy to use as ProSolus’ noninvasive and comfortable transdermal patches.
The expansion into transdermal delivery through the ProSolus acquisition continues to build on Mission’s founding principle of finding ways to solve unmet healthcare needs with novel solutions.
For more information, please visit prosoluspharma.com.